ArticleThe British journal of radiology2026
Upgrade and downgrade rates of fibroepithelial lesions in a B3 lesion cohort: a 15-year analysis from a university hospital.
Article in The British journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Surgical Excision Mandatory for Sclerosing Adenosis Diagnosed on Core Needle Biopsy? Multimodal Imaging Features and Upgrade Outcomes in a Symptomatic Cohort.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast lesions classified as B3 according to UK diagnostic guidelines pose significant management challenges due to their uncertain malignant potential. Within the B3 category, fibroepithelial lesions (FEL) include fibroadenomas (FA), where a phyllodes tumor (PT) cannot be excluded, and benign phyllodes tumors (BPT).
objectivesTo evaluate the upgrade and downgrade rates of B3 classified FA and BPT within a B3 lesion cohort, identify correlations with patient demographics and lesion characteristics, and assess the impact of other variables on diagnostic outcomes.
methodsOf a total of 332 B3 lesions, a study was conducted on 73 patients with B3-classified FA or BPT diagnosed on core needle biopsy between January 2010 and January 2025. Data on demographics, histological diagnosis, lesion size, imaging findings, procedural data, and subsequent histopathological diagnoses (upgrade or downgrade) were collected. Statistical analyses included multivariate logistic regression. All patients were followed for a median of 8 years.
resultsOf 73 FEL cases studied (36 B3-FA, 37 BPT), the B3-FEL downgrade rate was 37% (27/73), and the FEL upgrade rate was 15% (11/73). Downgraded lesions were associated with a significantly lower mean age (32.17 years vs. 40.65 years in non-downgraded lesions, P = .027). Multivariate logistic regression identified lower age as the only predictor for downgrade status. The overall long-term recurrence rate was 2.7%.
conclusionOur findings suggest that B3-FELs have high downgrade rates. Younger age is associated with downgrading, while lesion size and ultrasound score are not significant predictors of downgrade. A low long-term recurrence rate of 2.7% was observed. ADVANCES IN KNOWLEDGE: Given the substantially higher downgrade rates in younger patients and the low long-term recurrence rates for B3-FELs, multidisciplinary teams could refine risk stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.